NZ335003A - Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) - Google Patents

Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)

Info

Publication number
NZ335003A
NZ335003A NZ335003A NZ33500397A NZ335003A NZ 335003 A NZ335003 A NZ 335003A NZ 335003 A NZ335003 A NZ 335003A NZ 33500397 A NZ33500397 A NZ 33500397A NZ 335003 A NZ335003 A NZ 335003A
Authority
NZ
New Zealand
Prior art keywords
mpif
inhibitory factor
myeloid progenitor
methods
disease states
Prior art date
Application number
NZ335003A
Other languages
English (en)
Inventor
Reiner L Gentz
Vikram Patel
Brent L Kreider
Jun Zhang
Michael Antonaccio
Donna Mendrick
Pablo Jimenez
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NZ335003A publication Critical patent/NZ335003A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ335003A 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) NZ335003A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2729996P 1996-09-30 1996-09-30
US2730096P 1996-09-30 1996-09-30
PCT/US1997/017505 WO1998014582A1 (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (mpif-1), monocyte colony inhibitory factor (m-cif), and macrophage inhibitory factor-4 (mip-4)

Publications (1)

Publication Number Publication Date
NZ335003A true NZ335003A (en) 2000-11-24

Family

ID=26702293

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ335003A NZ335003A (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)
NZ506135A NZ506135A (en) 1996-09-30 1997-09-30 Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ506135A NZ506135A (en) 1996-09-30 1997-09-30 Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis

Country Status (8)

Country Link
EP (1) EP0941330A1 (zh)
JP (1) JP2001500382A (zh)
KR (1) KR20030097607A (zh)
CN (1) CN1239510A (zh)
AU (1) AU4657697A (zh)
CA (1) CA2267193A1 (zh)
NZ (2) NZ335003A (zh)
WO (1) WO1998014582A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6451562B1 (en) 1993-12-22 2002-09-17 Human Genome Sciences, Inc. Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
AU777297B2 (en) * 1996-09-30 2004-10-07 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
CA2350771A1 (en) 1998-11-10 2000-05-18 Human Genome Sciences, Inc. Chemokine .beta.-7
AU1891000A (en) * 1999-01-07 2000-07-24 Takeda Chemical Industries Ltd. Process for producing activated protein
AU1083401A (en) * 1999-10-14 2001-04-23 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US20030215460A1 (en) 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
KR100867257B1 (ko) * 2001-10-09 2008-11-11 케모센트릭스, 인크. 포밀 펩티드 수용체 유사 1 수용체에 대한 리간드로유용한 조성물 및 이의 사용 방법
US20070244037A1 (en) * 2003-10-24 2007-10-18 Tap Pharmaceutical Products Inc Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
WO2005093428A2 (en) * 2004-03-22 2005-10-06 Novartis Ag Chemokine ccl18 as a biomarker
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
JP5272011B2 (ja) * 2007-10-22 2013-08-28 セントビンセンツ ホスピタル シドニー リミテッド 予後判定の方法
CN113215085B (zh) * 2021-05-07 2024-05-10 澳门大学 一种脂类物质添加剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ271756A (en) * 1993-12-22 1998-02-26 Human Genome Sciences Inc Human macrophage inflammatory proteins and coding sequences, their production and use
JP3630685B2 (ja) * 1993-12-24 2005-03-16 ウルフ−ゲオルグ フォースマン ヒト循環サイトカインｃｃ−１
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
EP0871672A4 (en) * 1995-05-05 1999-05-12 Human Genome Sciences Inc CHIMIOKINE BETA-8, CHIMIOKINE BETA-1 AND PROTEIN 4 INFLAMMATORY FROM HUMAN ORIGINAL MACROPHAGES
EP0859842A4 (en) * 1995-09-29 1999-02-24 Smithkline Beecham Corp SHORT FORMS OF CHEMOKIN-g (b) -8
ZA968897B (en) * 1995-10-24 1998-07-14 Smithkline Beecham Corp Novel chemokine for mobilizing stem cells

Also Published As

Publication number Publication date
CN1239510A (zh) 1999-12-22
CA2267193A1 (en) 1998-04-09
JP2001500382A (ja) 2001-01-16
NZ506135A (en) 2002-11-26
AU4657697A (en) 1998-04-24
KR20030097607A (ko) 2003-12-31
EP0941330A1 (en) 1999-09-15
WO1998014582A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
NZ335003A (en) Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)
EP0735893A4 (en) CHANGING THE IMMUNE RESPONSE BY USING PAN DR BINDING PROTEINS
HK184896A (en) Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine
IL110672A0 (en) Therapeutic heterocycles
HUS1400034I1 (hu) Dialkil-fumarátok alkalmazása autoimmun betegségek kezelésére szolgáló gyógyászati készítmények elõállítására
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
IL138665A0 (en) Peptide factor
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
DE69912434D1 (de) Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung
HK1123741A1 (zh) 包含美沙芬 和奎尼丁 的神經系統疾病治療用藥物組合物
GB2314022B (en) Blending medical composition with sustained medicament releasability and process for preparing the same
HK1019856A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
JPH06329549A (ja) インターロイキン１２のｐ４０サブユニットを含んでなる医薬
CA2068871A1 (en) Non-glycosylated fgf-4 and compositions containing the same
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
DE69911401D1 (en) Immunoregulator
GR3034743T3 (en) Growth hormone antagonists.
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
HU9202075D0 (en) Bcrf1 proteins of gamma-interferon inhibiting effect
NO983238L (no) Exodus kjemokin materialer og fremgangsmÕter
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
AU4762893A (en) Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)